Biotalys Nv · EURONEXT:BTLS
Biotalys Nv — Investor Presentation (May 2026)
41 slides from Biotalys Nv's investor presentation, May 2026
Slide 1: Biotalys: Breakout leader in Precision Biocontrols
Biotalys: Breakout leader in Precision Biocontrols Investor Presentation | 2026
Slide 2: Disclaimer
Disclaimer • This presentation, including the oral presentation (together, the “Materials”) has been prepared by the management of Biotalys NV (the “Company”). The Materials must be treated confidentially and may not be distributed, passed on or otherwise disclosed. The Materials serve information p
Slide 3: Breakout leader in Precision Biocontrols in agriculture
Breakout leader in Precision Biocontrols in agriculture AGROBODY technology delivers efficacy of chemicals with safety & sustainability of biologicals • Dynamic, groundbreaking company in the Ghent biotech cluster, applying antibody technology in agriculture to create precision solutions for crop pr
Slide 4: Historical milestones
Historical milestones K&E Financing 2013 2016 2017 2021 2024 2026 milestones1 2019-20 2023 EUR 5m Series A EUR 8m 1st round EUR 3m 2nd round EUR 53m EUR 7m PIPE EUR 15m PIPE EUR 12m PIPE EUR 45m Series C of Series B of Series B successful IPO 2013 Founded Partnerships 2021 2021 2022 2022 2023 2025 2
Slide 5: Investment highlights
Investment highlights Unique technology platform Large and growing addressable market • Protein-based precision biocontrols • Significant market opportunity ($40bn+ global • Development cost one-tenth of chemicals fungicides/insecticides) • Combining the best of chemical efficacy • Focused pipeline
Slide 6: A Precision Biocontrol platform ready for commercial execution
Path to commercialisation A Precision Biocontrol platform ready for commercial execution A Precision Biocontrol platform ready for commercial execution Biotalys is transitioning from validation to commercial execution Commercial Efficacy Regulatory Commercialisation production Efficacy proven in mul
Slide 7: Strategic refocus and operational streamlining
Operating model Strategic refocus and operational streamlining What Changes Restructuring & Streamlining Quantified Impact Post-Reset Steady State Refocus organization on highest priority programs Headcount reduction, including leadership Streamline organization with new Reduced cash burn to end of
Slide 8: Clear valuation inflection point in next 12 – 36 months
Inflection points Clear valuation inflection point in next 12 – 36 months Primary value inflection: First meaningful EVOCA NG revenues in 2029 Transition from regulatory-validated asset to commercially proven platform Cumulative Path to First Commercial Revenues 2032 2029 2026 - 2027 2026 • Continue
Slide 9: Market opportunity
Market opportunity Spy: e biotalys “o%
Slide 10: Addressing unmet needs of farmers and society with new products that bridge the gap
Market opportunity Addressing unmet needs of farmers and society with new products that bridge the gap between biologicals and chemicals Farmers’ and Biotalys' AGROBODY societal needs technology Prevent annual crop loss of 20-40% New biological products to due to fungal diseases and pests1 sustainab
Slide 11: Growing $40bn addressable market for fungicides & insecticides
Market opportunity Growing $40bn addressable market for fungicides & insecticides Biotalys’ biological products address a large market where chemicals face serious regulatory and consumer pressure Biological solutions growing in importance as chemical portfolio shrinks Market in dire need of new act
Slide 12: Agriculture majors acquiring biological assets in race to fill portfolio gaps
Market opportunity Agriculture majors acquiring biological assets in race to fill portfolio gaps, validating sector Recent acquisitions in biological segment Sustainable solutions needed Portfolio gaps Biotalys proprietary technology Strong pipeline Strategic Resistance rationale for management acqu
Slide 13: Precision Biocontrols
Precision Biocontrols Spy: e biotalys “o%
Slide 14: Creating a new class of crop protection: Precision Biocontrols
Leadership in Precision Biocontrols Creating a new class of crop protection: Precision Biocontrols First mover advantage with no competitor as advanced in R&D, regulatory and distribution Precision Traditional Biocontrols biologicals Sustainability Proteins Macro-organisms Peptides Biochemicals Micr
Slide 15: AGROBODY: Proven platform designed for focused scale and optimized expansion
AGROBODYTM technology platform and pipeline AGROBODY : Proven platform designed for focused scale and optimized expansion • Validated beyond a single product, Transform blockers into precise Identify weak spots that control Harness nature’s antibody tools with EVOCA regulatory progress and to block
Slide 16: AGROBODY technology creating Precision Biocontrols: video
AGROBODY technology platform and pipeline AGROBODY technology creating Precision Biocontrols: video 16 https://biotalys.com/#video
Slide 17: Cost-to-market readiness one-tenth of chemicals
AGROBODY technology platform and pipeline Cost-to-market readiness one-tenth of chemicals AGROBODY biocontrols can be developed faster and at a fraction of the cost of chemicals AGROBODY biocontrols Chemical products R&D cost ~$25-30m1 ~$300-350m2 R&D 8-10 years +11 years time should decrease with l
Slide 18: Product pipeline
Product pipeline Spy: e biotalys “o%
Slide 19: Focused pipeline maximizes near-term value while preserving platform upside
Pipeline Focused pipeline maximizes near-term value while preserving platform upside Global Partnership Program Target Market Discovery Development Registration Market Size* Agreement EVOCA Botrytis, powdery High-value fruits & Pilot product 1st Gen mildew vegetables EVOCA Botrytis, powdery High-val
Slide 20: Field trial results with pilot product EVOCA prove efficacy against key fungal diseases
EVOCA Field trial results with pilot product EVOCA prove efficacy against key fungal diseases and validate technology platform Company-driven trials: Academic trials: Partner’s trials: explore and refine confirm performance validate and commit Field trial design Example: EVOCA's performance at flowe
Slide 21: EVOCA NG: First commercial product with optimised production
EVOCA NG EVOCA NG: First commercial product with optimised production EVOCA NG: First commercial product with optimised production Challenged conventional solutions Traditional biological solutions • Increased resistance to various widely used chemicals • Efficacy and consistency usually below chemi
Slide 22: BioFun-6 reduces dose rate, further contributing to cost efficiency
BioFun-6 BioFun-6 reduces dose rate, further contributing to cost efficiency A spray rotation program including first BioFun-6 candidate outperformed standard chemical rotation in 2025 trials Botrytis on grape cluster: UC Davis 2025 Remaining entrants showing higher average incidence of Chemical bot
Slide 23: BioFun-6 reduces dose rate, further contributing to cost efficiency
BioFun-6 BioFun-6 reduces dose rate, further contributing to cost efficiency A spray rotation program including first BioFun-6 candidate outperformed standard chemical rotation in 2025 trials Powdery mildew on grape cluster: UC Davis 2025 Remaining entrants showing higher average incidence of powder
Slide 24: Regulatory pressure and resistance against Botrytis fungicides create significant opportunity
Filling the portfolio gap - example Regulatory pressure and resistance against Botrytis fungicides create significant opportunity for Biotalys’ pipeline • Products worth +$120m are under medium to high resistance threat according to the Fungicide Resistance Action Committee (FRAC) • EVOCA obtained a
Slide 25: Regulatory inflection achieved with first of its kind protein pesticide registration in USA
Registration timelines Regulatory inflection achieved with first of its kind protein pesticide registration in USA Estimated registration timelines per geography 2025: EPA April 26: Public EVOCA H1 26: Florida consultation H2 26: California H2 26: Decision EVOCA NG 2029 2029-2030 BioFun-6 2030-31 20
Slide 26: Strategy
Strategy Spy: e biotalys “o%
Slide 27: Maximising in-house R&D focus and partner's capabilities in production scale and market reach
Strategy Maximising in-house R&D focus and partner’s capabilities in production scale and market reach 1 2 3 4 5 Upfront payments Cost compensation Milestone payments Royalties Traditional distribution Discovery ~80 % of In-house funds Development Production at scale Partnerships Limit capital outla
Slide 28: Strategic partnerships to accelerate commercialization
Production strategy Strategic partnerships to accelerate commercialization Strategic partnerships to accelerate commercialization Fermentation: Collaboration with 21st.BIO, specialist in precision fermentation to optimize production of active ingredients to achieve targets to be commercially competi
Slide 29: Protecting innovation with IP
IP strategy Protecting innovation with IP • Products, technology and know-how covered in 18 patent families with 73 active cases from which 27 patents are granted. • IP portfolio is a combination of patents on active ingredients and AGROBODY platform applications related to improvements in productio
Slide 30: Sustainability
Sustainability 30
Slide 31: Biotalys has sustainability at its core in line with UN SDGs
Sustainability Biotalys has sustainability at its core in line with UN SDGs Food Loss Human Capital Offer new tools to protect our food Offer equal chances and growth KPIs: Number of new MoAs, Number of application window KPIs : Engagement, Attrition, Learning, Diversity expansion Environmental prod
Slide 32: Benefits for biodiversity & soil
Sustainability Particularly relevant as pollinators appear Benefits for biodiversity & soil in the flowering phase of e.g. grapes Risks for bees and other pollinators negligible due to the targeted design of the bioactives Biodegradability of protein-based biocontrols without impact for mammals, bir
Slide 33: EVOCA best of class across key safety and environmental criteria
Sustainability EVOCA best of class across key safety and environmental criteria • Readily biodegradable, while none of the chemical fungicides we aim to replace meet biodegradability criteria • No toxicity-derived exposure limits whereas all competing actives show low safety limits for both dietary
Slide 34: Biotalys' laboratories obtained green label
Sustainability Biotalys’ laboratories obtained green label 34
Slide 35: Financial profile and investment highlights
Financial profile and investment highlights 35
Slide 36: FY 2025 key financial highlights
FY2025 FY 2025 key financial highlights In € thousands 2025 2024 Other operating income 3,043 3,183 Research and development expenses (13,272) (10,959) General and administrative expenses (5,615) (5,716) Operating loss (15,844) (13,492) Loss of the period (15,759) (13,188) Net cash inflow (outflow)
Slide 37: Outlook 2026
Outlook 2026 • Advance EVOCA NG in terms of process development as regulatory work and BioFun-6 with ongoing field trials • Continue optimizing production and manufacturing plans with 21st.Bio and network of CMO’s • Progress other pipeline programs BioFun-7 and BioIns-2, while opening BioFun-4 and -
Slide 38: Strong investor base; attractive upside potential by analysts
Financial profile Strong investor base; attractive upside potential by analysts Shareholders Recent share price evolution 15,4% 35,4% Free float 12,6% 11,5% <5,0% <5,0% 9,9% K&E 5,2% RMM Madeli % prior to PIPE announced on 6 May 2026 Analyst coverage Christian Faitz David Seynnaeve Guy Sips Target p
Slide 39: Investment highlights
Window of opportunity Investment highlights 1 2 3 Regulatory de-risked Commercial launch being prepared Partnership momentum building • EPA approval obtained (+ Florida state) • EVOCA Next Gen launching in 3 years • Major ag companies actively seeking biocontrols • EU review progressing with public
Slide 40: Board and ExCo combining the right experience for Biotalys
Leadership Board and ExCo combining the right experience for Biotalys Carlo Boutton Luc Van fraeyenhoven CFO CEO ad interim & CSO • 25+ years of experience in innovation • 30+ years of experience in the biotech with a focus on llama antibodies and automotive industries • Prior experience with: • Pre
Slide 41: Slide 41